Search Clinical Trials in the European Union

Duration
≤5 visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
141-160 of 525 trials

Mpox Vaccination Study: MPOX-VAX

We are studying a vaccine to see how well it prevents Mpox infection and how long the immune response lasts. Participants will also be monitored for other infections to understand overall health impacts.

Mpox Infection6-12 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementInfectious Diseases

Esophageal Strictures: Budesonide Tablets

We are studying whether budesonide tablets can help prevent esophageal strictures in adults after cancer surgery. This trial compares two doses of the medication to a placebo to assess effectiveness and safety.

Oesophageal Cancer and Related Conditions>2 yearsEfficacy phase (II)≤5 visitsInvestigational MedicinesGastroenterologyOncology

Scabies Treatment: Comparing Permethrin Creams

We are testing whether a new 10% permethrin cream works better than the standard 5% cream for treating scabies. We will also look at the safety of the new cream.

Scabies>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementDermatologyInfectious Diseases

Childhood Absence Epilepsy: Brivaracetam Safety Study

We are studying the long-term safety of brivaracetam in children and young adults with childhood or juvenile absence epilepsy. This research aims to understand how well the medication is tolerated over time.

Childhood Absence EpilepsyJuvenile Absence Epilepsy>2 yearsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteNeurologyPediatrics

INBRX-109 for Advanced Solid Tumors, Including Sarcomas

We are studying a new treatment, INBRX-109, in combination with chemotherapy for adults and adolescents with advanced solid tumors like Ewing sarcoma and colorectal cancer. The goal is to assess its safety and how well it works compared to current treatments.

Advanced or Metastatic Solid Tumors1-2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesOncology

Heart Procedure: Short vs. Long Antiplatelet Therapy

We are studying whether a shorter duration of antiplatelet therapy after a heart procedure is as safe and effective as the standard longer treatment. This trial is for patients who have had coronary angioplasty for blocked arteries.

Chronically Occluded Coronary Artery>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Dexamethasone for Severe Hospital-Acquired Pneumonia

We are studying whether dexamethasone can improve outcomes for critically ill patients with severe hospital-acquired pneumonia. This trial will also assess safety and how patients feel about the treatment.

Hospital-acquired Pneumonia>2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesInternal MedicinePulmonology

Meningococcal Vaccine Study for Infants and Toddlers

We are investigating a new meningococcal vaccine to see how well it works and its safety compared to an existing vaccine in healthy infants and toddlers. This study focuses on children receiving their first doses at 6-7 months and a booster at 12-13 months.

Meningococcal Infection6-12 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementInfectious DiseasesPediatrics

Meningococcal B Vaccine for Adults with Asplenia

We are studying the safety and immune response of the BEXSERO® vaccine in adults without a spleen. This trial compares their response to healthy individuals to ensure effective protection against meningococcal disease.

Splenectomy6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesInfectious DiseasesInternal Medicine

Ovarian Cancer: Niraparib Rechallenge Study

We are studying whether Niraparib can help ovarian cancer patients with oligometastatic progression after surgery live longer without their cancer worsening. The trial will also assess safety and various health indicators.

Ovarian Cancer with Oligometastatic Progression1-2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesGynecology and ObstetricsOncology

Ovarian Cancer: SALVOVAR Trial on Chemotherapy Regimens

We are studying whether a new weekly chemotherapy schedule improves outcomes for patients with poor prognostic ovarian cancer compared to the standard treatment. This trial aims to see if it helps with surgery success and overall survival.

Advanced Ovarian and Fallopian Tube Cancer>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsOncology

Meniscal Loss: Spongioflex® Allografts Study

We are investigating whether sterile allogeneic spongioflex® allografts can improve knee function in patients with incomplete meniscal loss. The study will also assess safety and patient satisfaction over several years.

Meniscus Tear>2 yearsMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOrthopedics and Traumatology

Liver Tumors: Indocyanine Green for Better Detection

We are testing whether a dye can help surgeons find liver tumors more easily during surgery. This study aims to improve surgical outcomes and understand how the dye behaves in the liver.

Resectable Malignant Liver Tumor>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteHepatologyOncology

Obstructive Sleep Apnea: Nacystelyn Inhaler Study

We are testing a new inhaler treatment for people with obstructive sleep apnea to see if it helps improve symptoms and reduce oxidative stress. The study also looks at the safety of this new treatment.

Obstructive Sleep Apnea≤3 monthsEfficacy phase (II)≤5 visitsStandard MedicinesCost ReimbursementNeurologyPsychiatryPulmonology

Atherosclerotic Cardiovascular Disease: Obicetrapib and Ezetimibe Study

We are testing a new combination therapy for people with atherosclerotic cardiovascular disease to see how it affects coronary plaque and overall heart health. This study aims to understand its safety and effectiveness compared to a placebo.

Atherosclerotic Cardiovascular Disease1-2 yearsConfirmation phase (III)≤5 visitsInvestigational MedicinesCardiologyEndocrinology

Advanced Epithelial Ovarian Cancer: Radspherin® Treatment

We are studying whether Radspherin® can improve survival and quality of life for patients with advanced ovarian cancer and peritoneal metastasis. This trial focuses on those scheduled for chemotherapy and surgery.

Peritoneal Carcinomatosis>2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesCost ReimbursementPartially RemoteGynecology and ObstetricsOncology

Alport Syndrome: Dapagliflozin for Kidney Health

We are studying whether Dapagliflozin can help slow the progression of kidney disease in adolescents and young adults with Alport syndrome. This trial aims to improve treatment options for those with this condition.

Alport's Syndrome>2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesInternal MedicineNephrology

Advanced Solid Tumors: D3S-001 Treatment Study

We are testing the safety and tolerability of D3S-001, alone or with other cancer medicines, for adults with advanced solid tumors that have a KRAS p.G12C mutation. This study aims to understand how the treatment works and its effects on tumors.

Advanced Solid Tumors with a KRAS p.G12C MutationSafety phase (I)Efficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Cirrhosis and Portal Hypertension: Metformin Study

We are investigating whether metformin can improve liver blood flow in patients with cirrhosis and portal hypertension. This study will also assess the safety of metformin and its effects on liver health.

Portal Hypertension1-2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesHepatologyInternal Medicine

Hyponatremia: Empagliflozin Treatment Study

We are investigating whether empagliflozin can help increase sodium levels in patients with euvolemic or hypervolemic hyponatremia. The study will also look at its effects on related symptoms and overall health.

Low Sodium Levels (Hyponatremia)≤3 monthsEfficacy phase (II)≤5 visitsStandard MedicinesEndocrinologyInternal Medicine